US FDA approves Vera's kidney disease drug
US FDA approves Vera's kidney disease drug July 7 (Reuters) - The U.S. Food and Drug Administration has approved Vera Therapeutics' VERA.O drug to treat patients with a potentially life-threatening kidney disease, the regulator said on Tuesday.
(Reporting by Siddhi Mahatole and Puyaan Singh in Bengaluru; Editing by Vijay Kishore)
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug